

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

30 May 2026

### Evaluation of treatment strategy Included : hydroxychloroquine ,naproxen and oseltamivir for outpatient patients with Covid 19

#### Protocol summary

##### Study aim

Determining the results of treatment strategy including oseltamivir, naproxen, hydroxychloroquine in outpatients with Covid 19

##### Design

Patients were treated with a treatment strategy after a certain diagnosis, based on clinical evidence and inflammatory examinations that did not have symptoms. Patients were divided into two groups in parallel; a group received only Hydroxychloroquine and Naproxen, and the second group, in addition to the two drugs, received Oseltamivir. both groups were treated to prevent the digestive effects of Pantoprazole therapeutic strategy by 20 mg twice, the symptoms and procedure of treatment of patient patients were followed.

##### Settings and conduct

Patients with Covid 19 referred to a specialized clinic for lung and office who receive oxygen saturation percentage less than 90% by receiving oxygen by reservation bag, provided the inclusion criteria, in two groups of 50 people as a control and intervention, The intervention group was treated with naproxen, hydroxychloroquine and oseltamivir and the second group were treated with naproxen hydroxychloroquine.

##### Participants/Inclusion and exclusion criteria

inclusion: Patients with Covid 19 coincide with disease confirmation Positive PCR test Bilateral lung involvement Having symptoms of the disease Minimum elementary literacy The patient should not participate in another trial. Oxygen saturation level below 90 ; exclusion: Lack of patient cooperation

##### Intervention groups

Intervention group: the three drugs Naproxen 500 mg twice daily, Hydroxychloroquine 200 mg twice daily, and Oseltamivir 75 mg twice daily for 5 days 5 days Control group: from two drugs Naproxen 500 mg twice, Hydroxychloroquine 200 mg twice a day

##### Main outcome variables

Status of symptoms

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20201202049566N1**

Registration date: **2021-01-22, 1399/11/03**

Registration timing: **retrospective**

Last update: **2021-01-22, 1399/11/03**

Update count: **0**

##### Registration date

2021-01-22, 1399/11/03

##### Registrant information

##### Name

akram asghari

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 25 3912 2000

##### Email address

aasgharii@muq.ac.ir

##### Recruitment status

##### Recruitment complete

##### Funding source

##### Expected recruitment start date

2020-02-20, 1398/12/01

##### Expected recruitment end date

2020-03-09, 1398/12/19

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Evaluation of treatment strategy Included :  
hydroxychloroquine ,naproxen and oseltamivir for  
outpatient patients with Covid 19

2020-08-25, 1399/06/04

**Ethics committee reference number**  
IR.MUQ.REC.1399.209

## Public title

treatment strategy Included: hydroxychloroquine,  
naproxen, and oseltamivir for outpatient patients with  
Covid 19

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Patients with Covid 19 with concurrent disease  
confirmation Positive PCR test Bilateral lung involvement  
Having symptoms of the disease Oxygen saturation  
level: below 90 does not participate in another trial least  
basic literacy

### Exclusion criteria:

Lack of cooperation

## Age

From **12 years** old to **70 years** old

## Gender

Both

## Phase

N/A

## Groups that have been masked

*No information*

## Sample size

Target sample size: **150**

## Randomization (investigator's opinion)

Not randomized

## Randomization description

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Qom University of Medical  
Sciences

##### Street address

blv.beheshti

##### City

Qom

##### Province

Ghous

##### Postal code

3719964797

## Approval date

## Health conditions studied

### 1

#### Description of health condition studied

COVID-19

#### ICD-10 code

U07.1

#### ICD-10 code description

COVID-19, virus identified

## Primary outcomes

### 1

#### Description

Having symptoms indicative of cough, shortness of  
breath, fever

#### Timepoint

Daily - 14 days after treatment

#### Method of measurement

questionnaire

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: The patient is quarantined at home  
for two weeks and uses two drugs, naproxen 500 mg  
twice daily, hydroxychloroquine 200 mg twice daily, and  
oseltamivir 75 mg twice daily for 5 days.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: The patient is quarantined at home for  
two weeks and uses two drugs, naproxen 500 mg twice  
daily, hydroxychloroquine 200 mg twice daily for 5 days.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Shahid Beheshti Hospital

##### Full name of responsible person

Seyed Hasan Adeli

##### Street address

Beheshti Blv  
**City**  
Qom  
**Province**  
Ghoum  
**Postal code**  
37719964797  
**Phone**  
+98 25 3612 2000  
**Email**  
adeli@muq.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**  
Ghoum University of Medical Sciences  
**Full name of responsible person**  
Ehsan Sharifipour  
**Street address**  
Safashahr  
**City**  
Qom  
**Province**  
Ghoum  
**Postal code**  
3719964797  
**Phone**  
+98 61 22000  
**Email**  
ehsansharifipour@gmail.com  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Ghoum University of Medical Sciences  
**Proportion provided by this source**  
30  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**  
Ghoum University of Medical Sciences  
**Full name of responsible person**  
Akram Asghari  
**Position**  
Assistant professor  
**Latest degree**

Subspecialist  
**Other areas of specialty/work**  
Internal Medicine  
**Street address**  
Beheshti hospital  
**City**  
Qom  
**Province**  
Ghoum  
**Postal code**  
3719964797  
**Phone**  
+98 25 3912 2000  
**Fax**  
**Email**  
aasgharii@muq.ac.ir

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**  
Ghoum University of Medical Sciences  
**Full name of responsible person**  
Akram Asghari  
**Position**  
Assistant professor  
**Latest degree**  
Subspecialist  
**Other areas of specialty/work**  
Internal Medicine  
**Street address**  
beheshti blv  
**City**  
Qom  
**Province**  
Ghoum  
**Postal code**  
3719964797  
**Phone**  
+98 25 3612 2000  
**Email**  
aasgharii@muq.ac.ir

## Person responsible for updating data

#### Contact

**Name of organization / entity**  
Ghoum University of Medical Sciences  
**Full name of responsible person**  
akram asghari  
**Position**  
Assistant professor  
**Latest degree**  
Subspecialist  
**Other areas of specialty/work**  
Internal Medicine  
**Street address**  
beheshti blv  
**City**  
Qom  
**Province**

Ghous

**Postal code**

3719964797

**Phone**

+98 25 3612 2000

**Email**

aasgharii@muq.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Not applicable

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to

make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

-

**When the data will become available and for how long**

-

**To whom data/document is available**

-

**Under which criteria data/document could be used**

-

**From where data/document is obtainable**

-

**What processes are involved for a request to access data/document**

-

**Comments**

-